The objective of the C-SiG Clinical Core is to provide a user-friendly, one-stop service to access digestive disease-related biospecimens for Center members. Under the direction of Dr. Lisa Boardman, a well-established clinician scientist with IRB and biobanking expertise, the organization and infrastructure of the CSiG Clinical Core provides essential expertise and personnel to advise and interact with C-SiG members in pursuit of two Specific Aims: First, to provide support to enhance existing individual Gl-related biobanks operating within the Clinical Core umbrella and develop future repositories. Second, to centralize, expedite, and facilitate access to Gl-related biobanks and utilization of Gl biospecimens for C-SiG members to translate signaling research within the paradigm of human specimens. To achieve these aims C-SiG Clinical Core: i) Provides a central access point and streamlined process for biospecimens requests;ii) Strengthens the existing Gl tissue biorepositories by facilitating new specimen collection, and, iii) Develops new tissue collections. The Core integrates existing resources from individual investigators in the Division of Gastroenterology and Hepatology and from institutional biospecimens repositories, providing a cost effective approach to collaboratively translate Gl signaling paradigms into human tissues. Additionally, the C-SiG Clinical Core has developed strong partnerships with the 1R6, anatomic pathology frozen section laboratories (aka TRAG;source of all surgical biospecimens), and the Pathology Research Core (facility that performs tissue sectioning, immunostaining, etc). These partnerships allow C-SiG Clinical Core personnel to expedite movement of protocols and projects through these key institutional resources. The primary services offered by the C-SiG Clinical Core are IR6 protocol development support, biospecimens request support (including identification of appropriate tissues, pathology review, &coordinating tissue processing), and biobank support services (IR6 protocol templates, tissue inventory management software, standardized questionnaires, daily searches of the surgical list for approved 1R6 protocols, and limited study coordinator support for consenting). In response to C-SiG member feedback, we have recently added services to support the collection of stool for human microbiome research. The C-SiG Clinical Core services have been used by 63% of Center members and have supported 49 publications.

Public Health Relevance

Gastrointestinal diseases and their complications have a significant effect on public health and health care utilization costs. The C-SiG Clinical Core supports scientific advancements of C-SiG members that are critically important for furthering understanding of the mechanisms that underlie digestive diseases, which can lead to practical applications for the diagnosis, prevention, monitoring and treatment of human disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK084567-06
Application #
8737728
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ni, Jun; Wangensteen, Kirk J; Nelsen, David et al. (2016) Active recombinant Tol2 transposase for gene transfer and gene discovery applications. Mob DNA 7:6
Landry, Greg M; Hirata, Taku; Anderson, Jacob B et al. (2016) Sulfate and thiosulfate inhibit oxalate transport via a dPrestin (Slc26a6)-dependent mechanism in an insect model of calcium oxalate nephrolithiasis. Am J Physiol Renal Physiol 310:F152-9
Ma, Alvin C; McNulty, Melissa S; Poshusta, Tanya L et al. (2016) FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science. Hum Gene Ther 27:451-63
Khanna, S; Montassier, E; Schmidt, B et al. (2016) Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 44:715-27
Druliner, Brooke R; Rashtak, Shahrooz; Ruan, Xiaoyang et al. (2016) Colorectal Cancer with Residual Polyp of Origin: A Model of Malignant Transformation. Transl Oncol 9:280-6
Tomita, Kyoko; Freeman, Brittany L; Bronk, Steven F et al. (2016) CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep 6:28786
Kawakami, Hisato; Huang, Shengbing; Pal, Krishnendu et al. (2016) Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther 15:3015-3027
Tabibian, James H; Varghese, Cyril; LaRusso, Nicholas F et al. (2016) The enteric microbiome in hepatobiliary health and disease. Liver Int 36:480-7
Verma, Vikas K; Li, Haiyang; Wang, Ruisi et al. (2016) Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol 64:651-60
Ding, Xiwei; Chaiteerakij, Roongruedee; Moser, Catherine D et al. (2016) Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget 7:20080-92

Showing the most recent 10 out of 399 publications